GlassScriptPhysician profile
Timothy D Martindale
NPI 1003824632
$10,549.92
in general payments reported to CMS, 2019-2025
52 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $1,075 · 2021: $1,194 · 2022: $1,783 · 2023: $1,955 · 2024: $1,859 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,804 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,803.94 |
| Education | $200.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,123.71 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $1,033.61 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Novo Nordisk INC | $908.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $790.78 | 2019-2025 | Rexulti, Nuedexta |
| Gilead Sciences, INC. | $788.84 | 2022-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $778.65 | 2019-2025 | Xifaxan |
| Amgen INC. | $520.18 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $465.57 | 2019-2025 | Belsomra, Vaxneuvance, Vaxelis |
| Corium, LLC | $421.56 | 2022-2025 | Azstarys |
| Astellas Pharma US INC | $329.15 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $324.77 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $299.01 | 2020-2025 | Trintellix |
| Bausch Health US, LLC | $209.48 | 2021-2023 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.59 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $183.68 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Martindale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.